Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alkermes plc
  6. News
  7. Summary
    ALKS   IE00B56GVS15

ALKERMES PLC

(ALKS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Alkermes : Morgan Stanley Adjusts Alkermes' Price Target to $22 From $16 on Cost Cutting Plan; Equal-Weight Rating Kept

12/21/2020 | 07:08am EDT


ę MT Newswires 2020
All news about ALKERMES PLC
09/13ALKERMES : to Present Two Posters on Investigational Immuno-oncology Candidate, Nemvaleuki..
PR
09/10ALKERMES : Announces Launch of 4th Annual Alkermes Pathways Research Awards Program
AQ
09/09ALKERMES : Announces Launch of 4th Annual Alkermes Pathways Research Awards« Program
PR
09/02ALKERMES : to Take Part in the Citi Annual BioPharma Virtual Conference
PR
09/02ALKERMES : BofA Securities Downgrades Alkermes to Underperform from Neutral on Risk/Reward..
MT
09/02ALKERMES : BofA Securities Downgrades Alkermes to Underperform from Neutral, Adjusts Price..
MT
08/04INSIDER TRENDS : Alkermes Insider 90-Day Buying Trend Prolonged with Purchase
MT
08/02ALKERMES : Secures FDA Fast Track Designation for Melanoma Treatment
MT
08/02ALKERMES : Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of M..
PR
08/02Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of ..
CI
More news
Analyst Recommendations on ALKERMES PLC
More recommendations
Financials (USD)
Sales 2021 1 173 M - -
Net income 2021 -80,0 M - -
Net cash 2021 384 M - -
P/E ratio 2021 -62,6x
Yield 2021 -
Capitalization 4 887 M 4 887 M -
EV / Sales 2021 3,84x
EV / Sales 2022 3,39x
Nbr of Employees 2 245
Free-Float 96,7%
Chart ALKERMES PLC
Duration : Period :
Alkermes plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALKERMES PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 30,29 $
Average target price 26,50 $
Spread / Average Target -12,5%
EPS Revisions
Managers and Directors
Richard F. Pops Chairman & Chief Executive Officer
Iain Michael Brown Senior VP, Chief Financial & Accounting Officer
Craig C. Hopkinson Chief Medical Officer & EVP-Research & Development
Thomas Harvey Chief Information Officer & Senior VP-IT
Sondra Smyrnios Senior Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
ALKERMES PLC51.83%4 887
MODERNA, INC.315.47%170 876
LONZA GROUP AG31.58%59 927
IQVIA HOLDINGS INC.43.03%48 510
CELLTRION, INC.-23.26%31 691
SEAGEN INC.-5.78%28 939